Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 608.50K | 723.50K | 676.70K | 799.10K | 1.05M |
| Depreciation & Amortization | 177.50K | 127.40K | 130.20K | 126.60K | 132.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 802.40K | 851.80K | 808.20K | 927.40K | 1.19M |
| Operating Income | -802.40K | -851.80K | -808.20K | -927.40K | -1.19M |
| Income Before Tax | -808.40K | -887.60K | -798.70K | -911.20K | -3.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -808.40K | -887.60K | -798.70K | -911.20K | -3.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -808.40K | -887.60K | -798.70K | -911.20K | -3.18M |
| EBIT | -802.40K | -851.80K | -808.20K | -927.40K | -1.19M |
| EBITDA | -669.90K | -770.60K | -725.50K | -866.80K | -1.06M |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.02 | -0.06 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.02 | -0.07 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 53.94M | 53.94M | 53.83M | 53.76M | 49.78M |
| Average Diluted Shares Outstanding | 53.94M | 53.94M | 53.83M | 53.76M | 49.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |